Immunocore Holdings plc (NASDAQ:IMCR) Poised To Extend Recent Momentum After Positive Q2 Business Update

Immunocore enters the near term with mixed technicals but clear fundamental strength from recent commercial and pipeline milestones. Liquidity and a high gross margin underpin a valuation that WMDST currently classifies as under-valued.

Recent News

On August 6, 2026 Immunocore reported second-quarter 2026 financial results and provided a business update, noting five-year overall survival data for KIMMTRAK presented at AACR 2026; the company had announced the timing of the Q2 results on July 30, 2026 and recently flagged participation at investor conferences in September 2026.

Technical Analysis

ADX / DI+ / DI-: ADX at 30.61 indicates a strong underlying directional move. DI+ peaked and reversed, a bearish directional shift; DI- dipped then reversed, which also reads as bearish. Together these directional indicators point to a recent loss of bullish directional conviction despite the stronger trend reading.

MACD: MACD shows a peak-and-reverse pattern, signaling bearish momentum, even though the MACD value (0.91) sits marginally above its signal line (0.88), representing a short-term bullish crossover that lacks confirmation from the trend reading.

MRO (Momentum/Regression Oscillator): MRO at 31.5 sits positive, which implies the price presently trades above the calculated target and therefore faces potential downward pressure; the MRO has peak-and-reversed, reinforcing the momentum warning.

RSI: RSI at 60.11 with a dip-and-reversal indicates renewed upward momentum in relative strength, but the level remains only mildly elevated rather than overbought, tempering the bullishness.

Moving averages, Ichimoku and Bollinger context: Price closed at $37.37, above the 12-day EMA ($36.49), 20-day average ($36.45) and the 50-day average ($34.20). The price sits just below the 1x upper Bollinger band ($37.44). Ichimoku Tenkan (35.73) and Kijun (34.99) lie below price and the cloud (Senkou A 32.61 / Senkou B 31.93) sits well under current levels, supporting an overall technical bias to the upside that conflicts with select momentum indicators.

Volume & volatility: Recent volume (220,688) runs below the 10/50/200-day averages, indicating muted participation on the latest price moves while 42-day and 52-week volatility remain low (0.02), implying consolidation with potential for directional expansion if momentum reasserts.

 


Fundamental Analysis

Top-line and growth: Total revenue stood at $115,927,000. YoY revenue growth equals 99.38%, and QoQ revenue growth equals 311.92%, showing rapid top-line expansion on the provided period basis.

Profitability: Gross margin registers at 99.061%, well above the industry peer mean of 78.086% and consistent with a high-margin commercial therapy. Operating margin equals -2.584% and EBIT margin equals 1.726%; the EBIT margin sits above the industry peer mean (‑92.864%) but below the industry peer median (22.839%). QoQ change in EBIT margin shows a -88.72% move and YoY change shows -123.55%, indicating sizeable short-term contraction from recent comparators on the provided metric.

Earnings and cash flow: Reported EPS was -$0.02 versus an estimate of $0.02, a negative surprise of $0.04 (EPS surprise ratio -200%). Operating income recorded -$2,996,000 while EBITDA reached $3,027,000. Operating cash flow $15,928,000 with free cash flow $15,142,000 yields a free cash flow yield near 0.93% on the provided basis; WMDST’s free cash flow assessment flags contraction in growth rates year-over-year.

Balance sheet and leverage: Cash stood at $484,920,000 with cash and short-term investments of $880,211,000. Current ratio equals 4.47 and quick ratio 4.44, showing substantial near-term liquidity. Total debt equals $434,959,000 with debt-to-equity of 1.036 (103.6%) and debt-to-EBITDA ~143.7, indicating meaningful leverage relative to current operating cash flow levels.

Valuation context: Market capitalization measures $1,623,641,330 while enterprise value equals $1,178,389,330 and an EV-to-revenue ratio near 10.16. Price-to-book sits at 3.87 (below the industry peer mean of 8.39), price-to-sales ~14.01, and the analyst price-target mean of $39.79 sits approximately 6.5% above the $37.37 close. The current valuation as determined by WMDST: under-valued.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-06-30
REPORT DATE: 2026-08-06
NEXT REPORT DATE: 2026-11-05
CASH FLOW  Begin Period Cash Flow 452.7 M
 Operating Cash Flow 15.9 M
 Capital Expenditures -786.00 K
 Change In Working Capital 7.4 M
 Dividends Paid
 Cash Flow Delta 32.2 M
 End Period Cash Flow 484.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 115.9 M
 Forward Revenue 342.5 M
COSTS
 Cost Of Revenue 1.1 M
 Depreciation 1.0 M
 Depreciation and Amortization 1.0 M
 Research and Development 73.9 M
 Total Operating Expenses 118.9 M
PROFITABILITY
 Gross Profit 114.8 M
 EBITDA 3.0 M
 EBIT 2.0 M
 Operating Income -3.00 M
 Interest Income 3.6 M
 Interest Expense 2.5 M
 Net Interest Income 520.0 K
 Income Before Tax -514.00 K
 Tax Provision 294.0 K
 Tax Rate 40.0 %
 Net Income -808.00 K
 Net Income From Continuing Operations -808.00 K
EARNINGS
 EPS Estimate 0.02
 EPS Actual -0.02
 EPS Difference -0.04
 EPS Surprise -200.0 %
 Forward EPS -0.19
 
BALANCE SHEET ASSETS
 Total Assets 1.1 B
 Intangible Assets
 Net Tangible Assets 419.8 M
 Total Current Assets 1.1 B
 Cash and Short-Term Investments 880.2 M
 Cash 484.9 M
 Net Receivables 95.3 M
 Inventory 7.8 M
 Long-Term Investments 18.5 M
LIABILITIES
 Accounts Payable 26.3 M
 Short-Term Debt
 Total Current Liabilities 235.2 M
 Net Debt
 Total Debt 435.0 M
 Total Liabilities 699.6 M
EQUITY
 Total Equity 419.8 M
 Retained Earnings -819.11 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 8.25
 Shares Outstanding 50.866 M
 Revenue Per-Share 2.28
VALUATION
 Market Capitalization 1.6 B
 Enterprise Value 1.2 B
 Enterprise Multiple 389.293
Enterprise Multiple QoQ 474.895 %
Enterprise Multiple YoY -305.865 %
Enterprise Multiple IPRWA IMCR: 389.293
high: 148.972
median: 38.141
mean: 19.856
low: -178.99
 EV/R 10.165
CAPITAL STRUCTURE
 Asset To Equity 2.667
 Asset To Liability 1.6
 Debt To Capital 0.509
 Debt To Assets 0.389
Debt To Assets QoQ -4.385 %
Debt To Assets YoY -3.641 %
Debt To Assets IPRWA high: 0.833
IMCR: 0.389
mean: 0.281
median: 0.223
low: 0.0
 Debt To Equity 1.036
Debt To Equity QoQ -6.379 %
Debt To Equity YoY -7.779 %
Debt To Equity IPRWA high: 1.704
IMCR: 1.036
mean: 0.303
median: 0.098
low: -0.777
PRICE-BASED VALUATION
 Price To Book (P/B) 3.868
Price To Book QoQ -3.555 %
Price To Book YoY -9.29 %
Price To Book IPRWA high: 18.326
mean: 8.391
median: 6.334
IMCR: 3.868
low: -9.25
 Price To Earnings (P/E) -1596.012
Price To Earnings QoQ -1384.712 %
Price To Earnings YoY 860.89 %
Price To Earnings IPRWA high: 160.554
median: 40.973
mean: 20.564
low: -176.575
IMCR: -1596.012
 PE/G Ratio 14.778
 Price To Sales (P/S) 14.006
Price To Sales QoQ -5.361 %
Price To Sales YoY -17.166 %
Price To Sales IPRWA high: 559.892
mean: 54.716
median: 20.828
IMCR: 14.006
low: 0.983
FORWARD MULTIPLES
Forward P/E -172.923
Forward PE/G 1.601
Forward P/S 5.176
EFFICIENCY OPERATIONAL
 Operating Leverage -10.119
ASSET & SALES
 Asset Turnover Ratio 0.106
Asset Turnover Ratio QoQ 6.086 %
Asset Turnover Ratio YoY 13.96 %
Asset Turnover Ratio IPRWA high: 0.511
mean: 0.116
IMCR: 0.106
median: 0.105
low: 0.0
 Receivables Turnover 1.314
Receivables Turnover Ratio QoQ -4.495 %
Receivables Turnover Ratio YoY -10.885 %
Receivables Turnover Ratio IPRWA high: 4.472
median: 1.538
mean: 1.444
IMCR: 1.314
low: 0.058
 Inventory Turnover 0.136
Inventory Turnover Ratio QoQ 134.289 %
Inventory Turnover Ratio YoY -20.058 %
Inventory Turnover Ratio IPRWA high: 2.707
mean: 0.492
median: 0.453
IMCR: 0.136
low: 0.029
 Days Sales Outstanding (DSO) 69.432
CASH CYCLE
 Cash Conversion Cycle Days (CCC) -4181.052
Cash Conversion Cycle Days QoQ 595.841 %
Cash Conversion Cycle Days YoY 92.43 %
Cash Conversion Cycle Days IPRWA high: 1415.294
median: 197.717
mean: 179.216
low: -771.823
IMCR: -4181.052
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.142
 CapEx To Revenue -0.007
 CapEx To Depreciation -0.766
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 814.0 M
 Net Invested Capital 814.0 M
 Invested Capital 814.0 M
 Net Tangible Assets 419.8 M
 Net Working Capital 815.8 M
LIQUIDITY
 Cash Ratio 3.742
 Current Ratio 4.469
Current Ratio QoQ 6.894 %
Current Ratio YoY -24.171 %
Current Ratio IPRWA high: 31.351
mean: 4.801
IMCR: 4.469
median: 3.163
low: 0.34
 Quick Ratio 4.436
Quick Ratio QoQ 6.981 %
Quick Ratio YoY -24.321 %
Quick Ratio IPRWA high: 16.477
IMCR: 4.436
mean: 2.803
median: 2.737
low: 0.811
COVERAGE & LEVERAGE
 Debt To EBITDA 143.693
 Cost Of Debt 0.347 %
 Interest Coverage Ratio 0.796
Interest Coverage Ratio QoQ -85.129 %
Interest Coverage Ratio YoY -127.873 %
Interest Coverage Ratio IPRWA high: 533.0
mean: 42.233
median: 2.337
IMCR: 0.796
low: -1501.103
 Operating Cash Flow Ratio -0.074
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 5937.137
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 4.414 %
 Revenue Growth 8.671 %
Revenue Growth QoQ 311.924 %
Revenue Growth YoY 99.379 %
Revenue Growth IPRWA high: 278.717 %
mean: 15.349 %
median: 11.617 %
IMCR: 8.671 %
low: -242.388 %
 Earnings Growth -108.0 %
Earnings Growth QoQ -23.765 %
Earnings Growth YoY -64.0 %
Earnings Growth IPRWA high: 185.714 %
median: 13.636 %
mean: 12.799 %
IMCR: -108.0 %
low: -155.294 %
MARGINS
 Gross Margin 99.061 %
Gross Margin QoQ -0.534 %
Gross Margin YoY 0.124 %
Gross Margin IPRWA high: 100.0 %
IMCR: 99.061 %
median: 79.764 %
mean: 78.086 %
low: -3.536 %
 EBIT Margin 1.726 %
EBIT Margin QoQ -88.72 %
EBIT Margin YoY -123.553 %
EBIT Margin IPRWA high: 103.704 %
median: 22.839 %
IMCR: 1.726 %
mean: -92.864 %
low: -3750.867 %
 Return On Sales (ROS) -2.584 %
Return On Sales QoQ -137.866 %
Return On Sales YoY -82.982 %
Return On Sales IPRWA high: 74.372 %
median: 30.748 %
IMCR: -2.584 %
mean: -75.531 %
low: -3837.989 %
CASH FLOW
 Free Cash Flow (FCF) 15.1 M
 Free Cash Flow Yield 0.933 %
Free Cash Flow Yield QoQ -194.721 %
Free Cash Flow Yield YoY -39.533 %
Free Cash Flow Yield IPRWA high: 13.067 %
IMCR: 0.933 %
median: 0.852 %
mean: 0.544 %
low: -26.527 %
 Free Cash Growth -197.339 %
Free Cash Growth QoQ 250.993 %
Free Cash Growth YoY -101.064 %
Free Cash Growth IPRWA high: 175.34 %
mean: 20.583 %
median: 1.424 %
IMCR: -197.339 %
low: -249.171 %
 Free Cash To Net Income -18.74
 Cash Flow Margin -15.044 %
 Cash Flow To Earnings 21.584
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) -0.074 %
Return On Assets QoQ -106.101 %
Return On Assets YoY -92.418 %
Return On Assets IPRWA high: 20.575 %
median: 0.317 %
IMCR: -0.074 %
mean: -4.032 %
low: -44.847 %
 Return On Capital Employed (ROCE) 0.226 %
 Return On Equity (ROE) -0.002
Return On Equity QoQ -105.827 %
Return On Equity YoY -92.757 %
Return On Equity IPRWA high: 0.462
median: 0.006
IMCR: -0.002
mean: -0.104
low: -0.887
 DuPont ROE -0.199 %
 Return On Invested Capital (ROIC) 0.147 %
Return On Invested Capital QoQ -92.744 %
Return On Invested Capital YoY -120.22 %
Return On Invested Capital IPRWA high: 30.797 %
median: 3.876 %
IMCR: 0.147 %
mean: -0.275 %
low: -27.378 %

Six-Week Outlook

Near-term signals present a mixed outlook. Momentum measures (MACD peak-and-reverse, MRO positive and directional indicators showing DI+ peak-and-reverse) warn of possible downward pressure or consolidation, while moving averages, Ichimoku placement and an RSI dip-and-reversal indicate residual upside support. Liquidity metrics and muted volume suggest moves may lack conviction until one set of signals confirms. For those monitoring directional risk, watch whether MACD falls back below its signal line alongside ADX remaining above 25 (would reinforce a directional move) versus sustained price stability above the 12-day EMA and Ichimoku support (would sustain upside bias). WMDST’s valuation assessment and cash-rich balance sheet provide a fundamental offset to short-term momentum deterioration.

About Immunocore Holdings plc

Immunocore Holdings plc (NASDAQ:IMCR) develops innovative immunotherapies aimed at treating cancer, infectious diseases, and autoimmune conditions. Based in Abingdon, UK, the company advances its proprietary ImmTAC technology platform to harness the body’s immune system in combating diseases. Immunocore’s leading product, KIMMTRAK, targets unresectable or metastatic uveal melanoma, offering a novel treatment option for patients. The company’s pipeline includes tebentafusp, currently progressing through Phase 2/3 trials for advanced cutaneous melanoma. Additionally, Immunocore evaluates IMC-F106C in Phase 3 trials for first-line advanced cutaneous melanoma and in Phase 1/2 trials for a range of tumors, such as ovarian and lung cancers. The company also explores therapies for colorectal, gastrointestinal, and viral infections with candidates like IMC-R117C and IMC-M113V. Committed to addressing unmet medical needs, Immunocore conducts preclinical trials targeting solid tumor cancers and type 1 diabetes. Founded in 1999, Immunocore leverages its expertise to deliver transformative therapies, aiming to improve patient outcomes across the globe.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.